United States: Wilmerhale Represents Aileron Therapeutics In IPO
Last Updated: July 17 2017

On June 28, 2017, Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares were offered by Aileron. In addition, Aileron granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock from the company at the public offering price. Aileron's common stock began trading on the NASDAQ Global Market under the ticker symbol "ALRN" on Thursday, June 29, 2017.

The WilmerHale team representing Aileron in its IPO was led by Stuart Falber and included Josh Fox, Craig Hilts, Tim Kulis, Mike Lopes and Jenna Ventorino.

View Aileron's press release.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By WilmerHale
By WilmerHale
By Alan Wilson, Jonathan Wolfman
By WilmerHale
By Anna Gaudoin
By Rachel Jacobson, Nathaniel Custer, Mark Hanin
By Leila Gaafar
By Paul M. Architzel, Anjan Sahni, Matthew Beville, Daniel Martin
By Glenn Luinenburg
By Rachel Jacobson, Andrew L. Spielman, Sarah Judkins
Tools
Print
Font Size:
Translation
Channels